Serum soluble CD23 levels in giant cell arteritis. 1996

P Roblot, and F Morel, and E Lelièvre, and M H Biais-Sauvètre, and D de Groote, and J L Preud'homme, and J C Lecron
Service de Medicine Interne, Chu la Miletrie, Poitiers, France.

Lymphocytes and monocytes express various levels of membrane-bound CD23, the low affinity receptor for IgE (Fc epsilon RII), and in some cases release it as a soluble form. Soluble CD23 (sCD23) has been implicated in the regulation of many immunological functions of T and B lymphocytes, macrophages and myeloid cells in humans. To study serum sCD23 levels in inflammatory conditions, we selected a systemic disease sensitive to corticotherapy, the giant cell arteritis, which is characterized by an inflammation of the temporal artery. Serum sCD23 levels, as measured by a radioimmunoassay, were increased in these patients, and returned to normal values within the 24 h following initiation of corticotherapy. The data suggest that the increase in sCD23 levels in giant cell arteritis results from an overproduction.

UI MeSH Term Description Entries
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities
D013700 Giant Cell Arteritis A systemic autoimmune disorder that typically affects medium and large ARTERIES, usually leading to occlusive granulomatous vasculitis with transmural infiltrate containing multinucleated GIANT CELLS. The TEMPORAL ARTERY is commonly involved. This disorder appears primarily in people over the age of 50. Symptoms include FEVER; FATIGUE; HEADACHE; visual impairment; pain in the jaw and tongue; and aggravation of pain by cold temperatures. (From Adams et al., Principles of Neurology, 6th ed) Aortic Arteritis, Giant Cell,Aortitis, Giant Cell,Arteritis, Temporal,Cranial Arteritis,Horton Disease,Horton Giant Cell Arteritis,Juvenile Temporal Arteritis,Temporal Arteritis,Arteritis, Giant Cell, Horton,Arteritis, Giant Cell, Horton's,Giant Cell Aortic Arteritis,Giant Cell Aortitis,Giant Cell Aortitis, Horton's,Giant Cell Arteritis, Horton,Horton's Disease,Horton's Giant Cell Arteritis,Aortitides, Giant Cell,Arteritides, Cranial,Arteritides, Giant Cell,Arteritides, Juvenile Temporal,Arteritides, Temporal,Arteritis, Cranial,Arteritis, Giant Cell,Arteritis, Juvenile Temporal,Cranial Arteritides,Giant Cell Aortitides,Giant Cell Arteritides,Hortons Disease,Juvenile Temporal Arteritides,Temporal Arteritides,Temporal Arteritides, Juvenile,Temporal Arteritis, Juvenile
D017455 Receptors, IgE Specific molecular sites on the surface of B- and T-lymphocytes which combine with IgEs. Two subclasses exist: low affinity receptors (Fc epsilon RII) and high affinity receptors (Fc epsilon RI). Antigens, CD23,CD23 Antigens,Fc Receptors, epsilon,Fc epsilon Receptor,Fc epsilon Receptors,IgE Receptor,IgE Receptors,Receptors, Fc epsilon,epsilon Fc Receptor,epsilon Fc Receptors,CD 23 Antigens,CD23 Antigen,Fc epsilon RI,Fc epsilon RII,Immunoglobulin E Receptor,Antigen, CD23,Antigens, CD 23,Fc Receptor, epsilon,Receptor, Fc epsilon,Receptor, IgE,Receptor, Immunoglobulin E,Receptor, epsilon Fc,Receptors, epsilon Fc,epsilon RI, Fc,epsilon RII, Fc,epsilon Receptor, Fc,epsilon Receptors, Fc

Related Publications

P Roblot, and F Morel, and E Lelièvre, and M H Biais-Sauvètre, and D de Groote, and J L Preud'homme, and J C Lecron
July 1972, Lancet (London, England),
P Roblot, and F Morel, and E Lelièvre, and M H Biais-Sauvètre, and D de Groote, and J L Preud'homme, and J C Lecron
October 1976, JAMA,
P Roblot, and F Morel, and E Lelièvre, and M H Biais-Sauvètre, and D de Groote, and J L Preud'homme, and J C Lecron
December 1999, Turkish journal of haematology : official journal of Turkish Society of Haematology,
P Roblot, and F Morel, and E Lelièvre, and M H Biais-Sauvètre, and D de Groote, and J L Preud'homme, and J C Lecron
May 1995, The Journal of dermatology,
P Roblot, and F Morel, and E Lelièvre, and M H Biais-Sauvètre, and D de Groote, and J L Preud'homme, and J C Lecron
April 1994, Clinical transplantation,
P Roblot, and F Morel, and E Lelièvre, and M H Biais-Sauvètre, and D de Groote, and J L Preud'homme, and J C Lecron
January 1995, Journal of investigational allergology & clinical immunology,
P Roblot, and F Morel, and E Lelièvre, and M H Biais-Sauvètre, and D de Groote, and J L Preud'homme, and J C Lecron
January 1996, Mediators of inflammation,
P Roblot, and F Morel, and E Lelièvre, and M H Biais-Sauvètre, and D de Groote, and J L Preud'homme, and J C Lecron
July 2006, The Journal of rheumatology,
P Roblot, and F Morel, and E Lelièvre, and M H Biais-Sauvètre, and D de Groote, and J L Preud'homme, and J C Lecron
January 1998, Clinical and experimental rheumatology,
P Roblot, and F Morel, and E Lelièvre, and M H Biais-Sauvètre, and D de Groote, and J L Preud'homme, and J C Lecron
June 1997, Blood,
Copied contents to your clipboard!